HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioCardia (NASDAQ:BCDA) and maintained a $4 price target.
October 11, 2023 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCardia's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $4.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for BioCardia. The maintained price target of $4 indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100